Vivek Subbiah/LinkedIn
Feb 1, 2025, 07:49
Vivek Subbiah: Revolutionizing Cancer Therapy – Breaking Barriers in Oncology with Tumor-Agnostic Drug Development
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Honored to deliver the opening keynote lecture ‘Revolutionizing Cancer Therapy: Breaking Barriers in Oncology with Tumor-Agnostic Drug Development’ at Oslo Cancer Cluster Cancer Crosslinks, Oslo, Norway.
Immense gratitude to the amazing Jutta Heix, Kjetil Tasken, Åsmund Flobak, Ali Areffard, Charlotte Homme, and the entire team for their incredible hospitality and terrific organization of the meeting.
The audience was fantastic, and the enthusiastic Q&A session was truly inspiring.
Thrilled to be talking to such dedicated colleagues all striving to eradicate cancer. ”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 23, 2025, 07:59
Jun 23, 2025, 07:42
Jun 23, 2025, 07:30